Last week, the largest randomized controlled trial ever conducted on a multi-cancer early detection (MCED) diagnostic test, Grail’s National Health Service England (NHS)-Galleri trial, reported topline results that did not meet the primary endpoint: the test did not reduce the number of cancers first diagnosed in Stage III and IV. In response, Grail’s stock dropped roughly 50%.
Want to stay in touch with the latest updates from Sitewide RSS Feed? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: ARK Invest | We Believe Innovation Is Key to Growth